If you write a blog — especially if you write one as part of your business — you’ll want to know about a new duplicate content vulnerability in WordPress and Movable Type. No, this isn’t the same old vulnerability that first hit the news last year — this is a new one, and this time it’s a bug.
Read More »
No Comments »
Headline writers are having a field day with the results of a meta-analysis to be published in The Lancet which found that cannabis users are 40% more likely than non-users to develop psychotic symptoms. Radio, print, and internet publications urge that more must be done to warn the public of the risks of cannabis use. But hold on, did the headline writers miss the lesson on correlation vs. causation in their Science for Journalists class?
Read More »
7 Comments »
Last year, I described my experiences trying to renew the digital certificate which enables this site to process data securely. Having battled with a company called RegisterFly, I wound up having a very pleasant experience with GoDaddy. Now a colleague who works in clinical trials has passed on news that the company I battled with was so bad it has actually been stripped of its ICANN accreditation. Caveat emptor!
Read More »
No Comments »
We hadn’t even announced it yet, but by last Friday afternoon astute readers were already signing up for our brand new newsletter! Just choose the topics you’d like to hear about, and we’ll package it all up into one newsletter and deliver it straight to you either once a day, or once a week. If you’d like to stay connected, what could be easier?
Read More »
No Comments »
If you’ve been following our articles on reader reports about the Daytrana ADHD patch, you’ll know that reader experiences vary widely. With over 170 comments about the methylphenidate transdermal patch, it’s time for another follow-up — and some additional resources for those experiencing problems with the patch.
Read More »
135 Comments »